Lv4
494 积分 2023-11-22 加入
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
7天前
已完结
Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
8天前
已完结
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage
12天前
已完结
A first-in-human Phase 1 study of LOXO-338, an oral selective Bcl-2 inhibitor, in patients with advanced hematologic malignancies
25天前
已完结
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
27天前
已完结
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
27天前
已关闭
Combination Therapy for EGFR -Mutated Lung Cancer
1个月前
已完结
A patent perspective of antiangiogenic agents
1个月前
已完结
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer
1个月前
已完结
皖公网安备34019202002308
